Document is current
Any future updates will be listed below
-
Authors
Bukkuri, Anuraag http://orcid.org/0000-0002-3616-626X
Pienta, Kenneth J.
Hockett, Ian
Austin, Robert H.
Hammarlund, Emma U.
Amend, Sarah R.
Brown, Joel S.
-
Funding
Funding for this research was provided by:
Stiftelsen Längmanska kulturfonden (BA22-0753)
Royal Swedish Academy of Sciences Stiftelsen GS Magnusons fond (MG2022-0019)
Crafoord Foundation (20220633)
National Science Foundation Graduate Research Fellowship Program (1746051)
NCI (U54CA143803, CA163124)
NCI (CA093900, CA143055)
Prostate Cancer Foundation
NCI (193489, R01CA258089)
Patrick C. Walsh Prostate Cancer Research Fund
Prostate Cancer Foundation
ParadOX-ERC Starting Grant (96948)
Swedish Research Council (2019-05254)
Crafoord Foundation (20220633)
Lund University
- License Information
-
More Information
Article History
Received: 13 September 2022
Accepted: 5 February 2023
First Online: 28 February 2023
Declarations
:
: KJP is a consultant for CUE Biopharma, Inc., and holds equity interest in CUE Biopharma, Inc., Keystone Biopharma, Inc. and PEEL Therapeutics, Inc. SRA holds equity interest in Keystone Biopharma, Inc. AB, IH, RHA, EUH, and JSB declare no potential conflict of interest.
